Poxvirus vaccines for cancer and HIV therapy

Expert Opinion on Biological Therapy

Volumn 4, Issue 4, 2004, Pages 575-588

  Essajee, Shaffiq ^b   Kaufman, Howard L ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Cancer; Dendritic cells; HIV; Paxviruses; Vaccines

Indexed keywords

EPITOPE; VIRUS ANTIGEN; VIRUS VACCINE; VIRUS VECTOR;

ANTIGEN EXPRESSION; CANCER; CLINICAL TRIAL; DENDRITIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; POXVIRUS; REVIEW; VACCINATION; VACCINIA; VIRUS RECOMBINANT;

AIDS VACCINES; ANIMALS; CANCER VACCINES; DENDRITIC CELLS; GENETIC VECTORS; HIV; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; POXVIRIDAE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS; MAMMALIA; POXVIRIDAE; VACCINIA VIRUS;

EID: 1842684059     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.4.575     Document Type: Review

References (88)

1. MOSS B: In: Field's Virology 4th ed., Knipe DM, Howley PM (Eds), Lipincott Williams & Wilkins: Philadelphia (2001):2849-2883.
2. REDFIELD RR, WRIGHT DC, JAMES WD, JONES TS, BROWN C, BURKE DS: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. (1987) 316(11):673-676.
3. MEYER H, SUTTER G, MAYR A: Mapping of the deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. (1991) 72(5):1031-1038.
4. CARROLL MW, MOSS B: Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology (1997) 238(2):198-211.
5. BHARDWAJ N: Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol. Med. (2001) 7(9):388-394.
6. BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Ann. Rev. Immunol. (2000) 18:767-811.
7. LARSSON M, FONTENEAU J-F, SOMERSAN S et al.: Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Ear. J. Immunol. (2001) 31:3432-3442.
8. ENGELMAYER J, LARSSON M, LEE A et al.: Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J. Virol. (2001) 75:2142-2153.
9. POPE M, GEZELTER S, GALLO N, HOFFMAN L, STEINMAN RM: Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells. J. Exp. Med. (1995) 182(6):2045-2056.
10. CAMERON PU, FREUDENTHAL PS, BARKER JM, GEZELTER S, INABA K, STEINMAN RM: Dendritic cells exposed to human immunodeficiency virus type-I transmit a vigorous cytopathic infection to CD4+ T cells. Science (1992) 257(5068):383-387.
11. CHEHIMI J, STARR SE, FRANK I et al.: Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J. Exp. Med. (1994) 179(4):1361-1366.
12. KANTOR J, IRVINE Y, ABRAMS S et al.: Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Int. (1992) 84(14):1084-1091.
13. WILLEY RL, BYRUM R, PIATAK M et al.: Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles. J. Virol. (2003) 77:1163-1174.
14. EARL PL, WYATT LS, MONTEFIORI DC et al.: Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology (2002) 294:270-281.
15. BAROUCH DH, SANTRA S, KURODA MJ et al.: Reduction of Simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia Ankara vaccination. J. Virol. (2001) 75(11):5151-5158.
16. MCANENY D, RYAN CA, BEAZLEY RM, KAUFMAN HL: Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann. Surg. Oncol. (1996) 3(5):495-500.
17. HORIG H, LEE DS, CONKRIGHT W et al.: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 costimulatory molecule. Cancer Immunol. Immunother. (2000) 49:504-514.
18. WEI X, DECKER JM, WANG S et al.: Antibody neutralization and escape by HIV-1. Nature (2003) 422(6929):307-312.
19. MOORE JP, PARREN PW, BURTON DR: Genetic subtypes, humoral immunity and human immunodeficiency virus type 1 vaccine development. J. Virol. (2001) 75(13):5721-5729.
20. LAMBERT JS, MCNAMARA J, KATZ SL et al.: Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG 218). J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. (1998) 19(5):451-461.
21. ESSAJEE SM, YOGEV R, POLLACK H, GREENHOUS B, KRASINSKI K, BORKOWSKY W: Recombinant glycoprotein vaccines for human immunodeficiency virus-infected children and their effects on viral quasispecies. Clin. Diagn. Lab. Immunol. (2002) 9(1):79-82.
22. MCELRATH MJ, COREY L, GREENBERG PD et al.: Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc. Natl. Acad. Sci. USA (1996) 93(9):3972-3977.
23. BETTS MR, AMBROZAK DR, DOUEK DC et al.: Analysis of total human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. (2001) 75(24):11983-11991.
24. KAUL R, ROWLAND-JONES SL, KIMANI J et al.: New Insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol. Lett. (2001) 79(1-2):3-13.
25. ADDO MM, ALTFELD M, ROSENBERG ES et al.: The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1 infected individuals. Proc. Natl. Acad. Sci. USA (2001) 98(4):1781-1786.
26. GRUTERS RA, VAN BAALEN CA, OSTERHAUS AD: The advantage of early recognition of HIV-infected cells by cytotoxic lymphocytes. Vaccine (2002) 20(15):2011-2015.
27. VAN BAALEN CA, PONTESELLI O, HUISMAN RC et al.: Human immunodeficiency virus type-1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J. Gen. Virol. (1997) 78(8):1913-1918.
28. HEL Z, VENZON D, POUDYAL M et al.: Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat. Med. (2000) 6(10):1140-1146.
29. SERH A, OURMANOV I, SCHMITZ JE et al.: Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. (2000) 74(6):2502-2509.
30. HEL Z, TSAI WP, THORNTON A et al.: Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen. J. Immunol. (2001) 167(12):7180-7191.
31. AMARA RR, VILLINGER F, ALTMAN JD et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine (2002) 20(15)-1949-1955. Recommended reading.
32. MASCOLA JR, NABEL GJ: Vaccine for the prevention of HIV-1 disease. Curr. Opin. Immunol. (2001) 13(4):489-495.
33. MCMICHAEL AJ, HANKE T: HIV vaccines 1983-2003. Nat. Med (2003) 9(7):874-880.
34. FLEURY B, JANVIER G, PIALOUX G et al.: Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with recombinant gp 160. J. Infect. Dis. (1996) 174(4):734-738.
35. EVANS TG, KEEFER MC, WEINHOLD KJ et al.: A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes alone, or with rgp 120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J. Infect. Dis. (1999) 180(2):290-298.
36. CAO H, KALEEBU P, HOM D et al.: Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 vaccine study. J. Infect. Dis. (2003) 187(6):887-895.
37. HANKE T, MCMICHAEL AJ, MWAU M et al.: Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine (2002) 20(15):1995-1998.
38. PARKER SL, TONG T, BOLDEN S, WINGO PA: Cancer statistics. CA Cancer J. Clin. (1997) 47:5-27.
39. DERMIME S, ARMSTRONG A, HAWKINS RE, STERN PL: Cancer vaccines and immunotherapy. Br. Med. Bull. (2002) 62:149-162.
40. PERALES MA, WOLCHOK JD: Melanoma vaccines. Cancer Invest. (2002) 20:1012-1026. Review of melanoma vaccines.
41. SCHUTZ A, OERTLI D, MARTI WR et al.: Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen. Cancer Gene Ther. (2001) 8:655-661.
42. ADAMS M, BORYSIEWICZ L, FIANDER A et al.: Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine (2001) 19:2549-2556.
43. KAUFMANN AM, STERN PL, RANKIN EM et al.: Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res. (2002) 8:3676-3685. Results showed the vaccination of rVV encoding E6 and E7 is well tolerated and produces HPV-specific CTL response.
44. ROSALES C, GRAHAM W, ROSAS GA, MERCHANT H, ROSALES R: A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol. Immunother. (2000) 49:347-360.
45. VALDEZ GV, SUTTER G, JOSE MV et al.: Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer (2000) 88:1650-1662.
46. CORONA GUTIERREZ CM, TINOCO A, LOPEZ CONTRERAS M et al.: Clinical protocol. A Phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum. Gene Ther. (2002) 13:1127-1140. Describes the most recent clinical trial
47. BERINSTEIN NL: Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J. Clin. Oncol. (2002) 20:2197-2207. Review on previous studies on CEA.
48. SCHMITZ J, REALI E, HODGE JW et al.: Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res. (2002) 62:5058-5064.
49. ZAREMBA S, BARZAGA E, ZHU M, SOARES N, TSANG KY, SCHLOM J: Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. (1997) Cancer Res. 57(20):4570-4577.
50. MARSHALL JL, HOYER RJ, TOOMEY MA et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. (2000) 18:3964-3973. First Phase I study with prime-boost strategies in patients.
51. HODGE JW, SCHLOM J, DONOHUE SJ et al.: A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a tion-human primate. Int. J. Cancer (1995) 63:231-237.
52. TERASAWA H, TSANG KY, GULLEY J, ARLEN P, SCHLOM J: Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin. Cancer Res. (2002) 8:41-53.
53. EDER JP, KANTOFF PW, ROPER K et al.: A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. (2000) 6:1632-1638.
54. GULLEY J, CHEN AP, DAHUT W et al.: Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 53:109-117. Results show the antitumour effects of RV-PSA in prostate cancer patients.
55. KAUFMAN HL, WANG W, MANOLA J et al.: Prime/boost vaccination using poxviruses expressing PSA in DO prostate cancer: preliminary results of ECOG 7897, a randomized Phase II clinical trial. Proc. Am. Soc. Clin. Oncol. (2002) 21:4a.
56. SCHOLL SM, BALLOUL JM, LE GOC G et al.: Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. (2000) 23:570-580. Results show the use of rVV on breast cancer patients.
57. ZALOUDIK J, LI W, JACOB L et al.: Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther. (2002) 9:382-389.
58. HOLLSTERIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS CC: p53 mutations in human cancers. Science (1991) 253:49-53.
59. ROSENWIRTH B, KUHN EM, HEENEY JL et al.: Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques. Vaccine. (2001) 19(13-14):1661-1670.
60. ODIN L, FAVROT M, POUJOL D et al.: Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53. Cancer Gene Ther. (2001) 8:87-98.
61. VAN DER BURG SH, MENON AG, REDEKER A et al.: Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin. Cancer Res. (2002) 8:1019-1027. Describes the effects of ALVAC-p53 on colorectal cancer patients in Phase I/II study.
62. MEKO JB, YIM JH, TSUNG K, NORTON JA: High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res. (1995) 55:476-770.
63. MASTRANGELO MJ, MAGUIRE HC, LATTIME EC: Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv. Evp. Med. Biol. (2000) 465:391-400.
64. QIN H, VALENTINO J, MANNA S et al.: Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Mol. Ther. (2001) 4:551-558.
65. CHEN B, TIMIRYASOVA TM, GRIDLEY DS, ANDRES ML, DUTTA-ROY R, FODOR I: Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy. Cytokine (2001) 15:305-314.
66. KAUFMAN HL, FLANAGAN K, LEE CS, PERETRA DJ, HORIG H: Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine (2002) 20:1862-1869.
67. KASS E, PANICALI DL, MAZZARA G, SCHLOM J, GREINER JW: Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cell and acts as an immunoadjuvant. Cancer Res. (2001) 61:206-214.
68. GRIFFITH TS, KAWAKITA M, TIAN J et al.: Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J. Natl. Cancer Int. (2001) 93:998-1007.
69. YANG AS, MONKEN CE, LATTIME EC: Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res. (2003) 63(20):6956-6961.
70. CHEN L, ASHE S, BRADY WA et al.: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 71:1093-1102.
71. TOWNSEND SE, ALLISON JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 259:368-370.
72. SCHWARTZ RH: Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell (1992) 71(7):1065-1068.
73. CARRENO BM, COLLINS M: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Ann. Rev. Immunol. (2002) 20:29-53.
74. HODGE JW, GROSENBACH DW, RAD AN, GIULIANO M, SABZEVARI H, SCHLOM J: Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine (2001) 19:3552-3567.
75. RAD AN, SCHLOM J, HODGE J: Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors. Crit. Rev. Oncol. Hematol. (2001) 39(1-2):43-57.
76. AARTS WM, SCHLOM J, HODGE JW: Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res. (2002) 62:5770-5777. Addition of combination of TRICOM and cytokine (GM-CSF and IL-2) in prime-boost strategies generated enhanced T cell responses.
77. GREINER JW, ZEYTIN H, ANVER MR, SCHLOM J: Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. (2002) 62(23):6944-6951.
78. GROSENBACH DW, BARRIENTOS JC, SCHLOM J, HODGE J: Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. (2001) 61(11):4497-4505.
79. KAUFMAN HL, CHEUNG K, HASKALL Z et al.: Intra-lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer. Hum. Gene Ther. (2003) 14:803-827.
80. VON MEHREN M, ARLEN P, GULLEY J et al.: The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. (2001) 7:1181-1191. Shows that a dual gene avipox containing CEA and B7.1 gene can generate increased CEA-specific precursors in human.
81. BAROUCH DH, SANTRA S, SCHMITZ JE et al.: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cyrokine-augmented DNA vaccination. Science (2000) 290(5491):486-492.
82. BAROUCH DH, SANTRA S, TENNER-RACZ K et al.: Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J. Immunol. (2002) 168(2):562-568.
83. SHANKAR P, SCHLOM J, HODGE JW: Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3). Vaccine (2001) 20:744-755.
84. STITTELAAR KJ, GRUTERS RA, SCHUTREN M et al.: Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine (2002) 20(23-24):2921-2927.
85. ZEH HJ, BARTLETT DL: Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther. (2002) 9(12):1001-1012.
86. MORSE MA, NAIR SK, BOCZKOWSKI D et al.: The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int. J. Gastrointest. Cancer (2002) 32(1):1-6.
87. MORSE MA, NAIR SK, MOSCA PJ et al.: Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. (2003) 21(3):341-349.
88. LU W, WU X, LU Y, GUO W, ANDRIEU JM: Therapeutic dendritic cell vaccine for simian AIDS. Nat. Med. (2003) 9(1)27-32.